Filing Flows › Ocular Therapeutix (OCUL) › Q4 2024
Ocular Therapeutix (OCUL) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 3, 2025
Ocular Therapeutix (OCUL) reported revenue of $17.1M for the fourth quarter 2024 (Q4 2024), +15% from a year earlier and +11% from the quarter before. Operating margin was -296.1%, net loss $48.4M (283.3% of revenue).
Ocular Therapeutix, Q4 2024: revenue $17.1M (+15% year over year), operating margin -296.1%, net loss $48.4M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.1M | +11% | +15% |
| Operating profit | −$50.6M | — | — |
| Net earnings | −$48.4M | — | — |
| Operating cash flow | −$39.4M | — | — |
What changed
Revenue was $17.1M in Q4 2024, up 15% year over year and up 11% from the previous quarter. Product revenue, net was the largest line at 100% of revenue.
Operating costs exceeded revenue by $50.6M, an operating margin of -296.1%. Total costs grew 94% against revenue growth of 15%. The fastest-growing cost line was Research & development (+153%). The quarter ended with a net loss of $48.4M, wider than the previous quarter's $36.5M loss.
Operating cash flow was −$39.4M. Non-cash charges added back $1.0M of depreciation and amortization and $7.2M of share-based compensation. Capital expenditures of $202K exceeded it, leaving free cash flow of −$39.6M.
Questions
What was Ocular Therapeutix's revenue in the fourth quarter 2024?
Ocular Therapeutix (OCUL) reported revenue of $17.1M for the fourth quarter 2024 (Q4 2024), +15% from a year earlier and +11% from the quarter before.
Was Ocular Therapeutix profitable in the fourth quarter 2024?
Operating loss was $50.6M (-296.1% of revenue) and net loss $48.4M.
Source: Ocular Therapeutix 10-K on SEC EDGAR.